LY-33169

LY-33169 is an experimental antitumor agent exhibiting selective cytotoxicity against multiple cancer cell lines, including Colon Adenocarcinoma-38, Human Colon-116, Human Prostate LNCaP, and Human Breast WSU-Br-1, LY-33169 demonstrates notable curative activity in murine tumor models either alone or in combination with LY-32262. LY-33169 also shows broad antitumor sensitivity across diverse malignancies, with reported log-kill values such as Panc-03 (2.4 LK), Panc-02 (2.9–4.1 LK), Squamous Lung LC-12 (2.1 LK), Colon-26 (2.2 LK), AML1498 (2.7 LK), Human Small Cell Lung DMS-273 (6.3 LK), Human Squamous Lung 165 (3.7 LK), Human Ovarian BG-1 (3.7 LK), Human Colon CX-1 (1.6 LK), Human Colon-15/MDR (2.3 LK), and Human CNS gliosarcoma SF295 (3.8 LK), illustrating its broad-spectrum potency and relevance for antitumor drug-development studies.